Notes on Helicobacter pylori Eradication Therapy: Regimens, Resistance, and Implications

Eradication therapy for Helicobacter pylori is used as first-line and, when needed, second-line treatment.
The most important driver of success is whether H. pylori is resistant to the drugs used; resistance guides choosing regimens and whether to pursue second-line therapy.
Culture and, more recently, PCR testing for H. pylori play roles in guiding therapy decisions.
Outcome assessment after therapy is important and is usually done with non-invasive breath tests; repeat gastroscopy is used occasionally when needed.

Regimen: a proton pump inhibitor (PPI) combined with amoxicillin and clarithromycin (a macrolide).
Dosing/duration: administered for $7\text{ days}$ , with the dosing given as $2\times\text{ daily}$ (twice daily).
Rationale: this regimen has been studied and used as the standard first-line therapy in Australia.
Adverse effects:
- Serious adverse effects are uncommon.
- Common issues related to amoxicillin include allergy and diarrhea; other minor adverse effects are possible.
If first-line therapy fails, management typically occurs in primary care with referrals to specialists, as there is no currently marketed second-line therapy specifically for general practitioners.

Pre-treatment resistance patterns influence success:
- Erythromycin (azithromycin) resistance is very low in Australia because it is not widely used as monotherapy for other infections.
- Metronidazole resistance is relatively high, around $50\%$ pre-treatment.
Pre-treatment resistance to metronidazole and erythromycin helps explain why those drugs are not ideal components of first-line triple therapy in Australia.
Outcome assessment is important to determine whether therapy succeeded; this is usually done with breath tests (non-invasive); gastroscopy may be repeated in selected cases.

Twenty years of multicenter Australian data show that results of first-line therapy with clarithromycin have been relatively stable over time.
Reason: clarithromycin resistance appears to have remained stable in the study populations.
In countries with high clarithromycin resistance (often due to poor antibiotic stewardship), eradication results have fallen, necessitating attribution to alternative regimens.

When treatment fails, secondary clarithromycin resistance frequently develops.
Among the approximately $20\%$ of people who fail first-line therapy, secondary resistance to clarithromycin is so common that repeating the same treatment yields dismal eradication rates.
A similar pattern occurs with metronidazole if it was used in early triple therapy; secondary resistance can undermine retreatment with the same regimen.

H. pylori is a curable infectious cause of a condition that was historically considered idiopathic.
This bacterium has prompted consideration of whether chronic inflammatory problems (e.g., gastrointestinal and systemic inflammatory conditions) may be influenced by an infectious trigger.
Examples discussed historically include questions about triggers in colitis (e.g., ulcerative colitis) and in rheumatoid arthritis, and whether such conditions are driven by an endogenous immune process or by an external bug.
To date, there has not been a breakthrough analogous to H. pylori’s impact on understanding gut disease.

H. pylori causes gastritis in all infected individuals.
Peptic ulcer disease occurs in a subset of infected people.
A fraction of infected individuals develop gastric cancer, but this occurs in only a few percent of carriers, despite the high prevalence of infection worldwide.
The global burden is large because a vast number of people carry the bacterium.

At the outset of the seminar, a set of patients were shown who shared a common feature: most were thought to have peptic ulcer disease (PUD).
A concise summary for further reading is by Hazel Mitchell (UNSW) and the lecturer, available in the MJA (Medical Journal of Australia) a few years ago, which provides an up-to-date synthesis of these points.
For a compact reference, look up the MJA summary by Mitchell and the lecturer.

First-line therapy in Australia: $ext{PPI} + ext{amoxicillin} + ext{clarithromycin}$ for $7\,\text{days}$ ; administer with or without monitoring for adverse effects.
Resistance is the main determinant of success; pre-treatment metronidazole resistance is about $50\%$ ; erythromycin resistance is low.
When therapy fails, secondary resistance to clarithromycin is common; retreatment with the same regimen is often not effective.
Culture and PCR testing can inform treatment choices; outcome assessment is typically via breath testing, with gastroscopy used in select cases.
H. pylori provides a framework for thinking about infectious triggers in idiopathic diseases and the broader implications for chronic inflammatory conditions, though a universal breakthrough analogous to H. pylori has not emerged for other conditions.
For deeper reading, refer to the MJA summary by Hazel Mitchell and the lecturer.